Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Other Pediatric Vaccines in Healthy Toddlers
Sponsor: Sanofi Pasteur, a Sanofi Company
This PHASE3 trial investigates Meningitis, Meningococcal and is currently completed. Sanofi Pasteur, a Sanofi Company leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — May 2022 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Aug 2019 — Jul 2020 [monthly]
Completed PHASE3
-
Mar 2019 — Aug 2019 [monthly]
Completed PHASE3
-
Aug 2018 — Mar 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE3
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi Pasteur, a Sanofi Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Acapulco, Mexico , Ansan, South Korea , Anyang, South Korea , Barnaul, Russia , Daegu, South Korea , Daejeon, South Korea , Gwangju, South Korea , Ilsan, South Korea , Incheon, South Korea , Jeju City, South Korea and 19 more locations